GE HealthCare Q2: Record Orders, Backlog, and Reaffirmed Guidance
GEHC sits 15% above its 52-week low of $58.75.
Summary
GE HealthCare posted Q2 2026 results featuring record orders and backlog, 5.7% revenue growth, and reaffirmed full-year guidance, alongside a strategic review of its challenged Patient Care Solutions segment.
Key Events · Earnings and Guidance · GEHC
-
Record Orders and Backlog
Organic orders surged 11.1% year-over-year, yielding a book-to-bill of 1.15x and lifting the backlog to $23.9 billion.
-
Revenue and Earnings Beat
Revenue reached $5.3 billion, up 5.7% (organic growth 3.5%); diluted EPS rose 16.5% to $1.24, and Adjusted EPS increased 6.6% to $1.13.
-
Full-Year Guidance Reaffirmed
The 2026 outlook was reaffirmed: organic revenue growth of 3-4%, Adjusted EBIT margin of 15.4-15.7%, Adjusted EPS of $4.80-$5.00, and free cash flow of approximately $1.6 billion.
-
Strategic Review of Patient Care Solutions
Management is evaluating strategic options for the Patient Care Solutions segment, which suffered a 13.3% revenue decline and a negative segment EBIT margin.
Analysis · GEHC · Industrial Applications And Services
A standout quarter for GE HealthCare was anchored by record organic orders growth of 11.1% and a book-to-bill of 1.15x, swelling the backlog to $23.9 billion. Revenue climbed 5.7% to $5.3 billion, propelled by Pharmaceutical Diagnostics and Advanced Imaging Solutions, while persistent weakness in Patient Care Solutions triggered a strategic review. The company reaffirmed its full-year 2026 guidance, underscoring confidence in sustained demand. The quarter also benefited from tariff refunds, and the share buyback program continued with $200 million in repurchases.
At the time of this filing, GEHC was trading at $67.80 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $29.2B. The 52-week trading range was $58.75 to $89.77. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.